22157.jpg
Global Neurorehabilitation Devices Industry (2020 to 2027) - Key Market Trends and Drivers
21 juin 2021 08h18 HE | Research and Markets
Dublin, June 21, 2021 (GLOBE NEWSWIRE) -- The "Neurorehabilitation Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19...
22157.jpg
Insights on the Spinal Cord Trauma Treatment Global Market to 2027 - Featuring Acorda Therapeutics, BioTime and Pfizer Among Others
21 juin 2021 08h13 HE | Research and Markets
Dublin, June 21, 2021 (GLOBE NEWSWIRE) -- The "Spinal Cord Trauma Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
16 juin 2021 08h00 HE | Neurona Therapeutics
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus 5% in the control group Data demonstrate...
22157.jpg
The Worldwide Neurovascular Devices/Interventional Neurology Industry is Expected to Reach $3.8 Billion by 2026 at a CAGR of 8.6% from 2021
10 juin 2021 05h53 HE | Research and Markets
Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "Global Neurovascular Devices/Interventional Neurology Market by Product (Embolization (Coil, Flow Diverter), Stents, Balloon Occlusion Devices, Clot...
Logo-FullColour.png
Highmark Innovations Inc. Completes a Brokered Private Placement Financing, Closes Acquisition of BrainFx Inc. and Announces Future Acquisitions, Solidifying Its Position as a Digital Health Leader in Brain and Mental Wellness
08 juin 2021 09h17 HE | Highmark Interactive
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Highmark Innovations Inc. (operating as ‘Highmark Interactive’) (“Highmark”) is pleased to announce the completion of its brokered private placement...
cognos.jpg
Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services
01 juin 2021 15h49 HE | Cognos Therapeutics Corp.
INGLEWOOD, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Cognos Therapeutics Corp. (“Cognos”, the Company”), an advanced medical device company focused on creating unique...
researchdrivelogo.jpg
Global Plasma Fractionation Market set to Garner Revenue of $45,803.2 Million at a CAGR of 7.0% from 2020-2027 - Exclusive Report [Pages-165] by Research Dive
24 mai 2021 09h05 HE | Research Dive
New York, USA, May 24, 2021 (GLOBE NEWSWIRE) -- According to the latest estimates by Research Dive, the global plasma fractionation market is predicted to experience a rise in revenue from $25,404.5...
brsf.png
Brain Scientific Receives Purchase Order and Begins Shipping Its Pediatric NeuroCap™ EEG Headsets
24 mai 2021 08h30 HE | Brain Scientific Inc.
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF) (the “Company”), a neurology-focused medical device and software company, today announces that...
logo.png
Nexstim Receives an NBS System Order from Australia
19 mai 2021 05h00 HE | Nexstim Oyj
Press release, Helsinki, 19 May 2021 at 12 PM (EEST) Nexstim Receives an NBS System Order from Australia Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company”) announces having received a...
logo.png
Nexstim granted authorization for commercial distribution of NBS system in Australia
18 mai 2021 03h00 HE | Nexstim Oyj
Press release, Helsinki, 18 May 2021 at 10 AM (EEST) Nexstim granted authorization for commercial distribution of NBS system in Australia Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company”)...